Your browser is no longer supported. Please, upgrade your browser.
Settings
EGRX Eagle Pharmaceuticals, Inc. daily Stock Chart
EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Index- P/E8.49 EPS (ttm)5.95 Insider Own11.53% Shs Outstand15.50M Perf Week-9.41%
Market Cap783.52M Forward P/E12.77 EPS next Y3.96 Insider Trans-1.79% Shs Float13.42M Perf Month-15.90%
Income96.70M PEG0.57 EPS next Q0.80 Inst Own- Short Float25.85% Perf Quarter-32.37%
Sales245.90M P/S3.19 EPS this Y-25.40% Inst Trans2.25% Short Ratio8.82 Perf Half Y-40.62%
Book/sh10.86 P/B4.65 EPS next Y6.97% ROA48.00% Target Price72.75 Perf Year-20.73%
Cash/sh- P/C- EPS next 5Y15.00% ROE65.70% 52W Range45.05 - 97.15 Perf YTD-36.29%
Dividend- P/FCF10.28 EPS past 5Y58.40% ROI53.80% 52W High-47.97% Beta1.22
Dividend %- Quick Ratio3.80 Sales past 5Y81.90% Gross Margin75.20% 52W Low12.21% ATR2.12
Employees77 Current Ratio3.90 Sales Q/Q22.50% Oper. Margin32.20% RSI (14)26.28 Volatility4.02% 3.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-64.80% Profit Margin39.30% Rel Volume0.87 Prev Close51.55
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout0.00% Avg Volume393.20K Price50.55
Recom2.30 SMA20-11.91% SMA50-9.66% SMA200-29.29% Volume343,880 Change-1.94%
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Jul-29-15Reiterated Piper Jaffray Overweight $94 → $119
Jul-06-15Reiterated Piper Jaffray Overweight $75 → $94
Jun-16-15Reiterated Cantor Fitzgerald Buy $65 → $95
Apr-20-15Reiterated Piper Jaffray Overweight $55 → $75
Mar-10-14Initiated William Blair Outperform
Oct-15-17 12:00PM  3 Biotech Values in a Fully Valued Market TheStreet.com
Oct-13-17 10:44AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017 Capital Cube
Oct-11-17 08:23AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017 Capital Cube
Oct-02-17 10:49AM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-28-17 04:21PM  Edited Transcript of EGRX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Sep-25-17 08:52AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017 Capital Cube
Sep-22-17 07:40AM  Corporate News Blog - Eagle Pharmas Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products ACCESSWIRE
Sep-20-17 06:50AM  Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited Business Wire
Sep-19-17 11:08PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017 Capital Cube
07:57PM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : September 19, 2017 Capital Cube
Sep-18-17 09:25AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017 Capital Cube
Sep-06-17 06:50AM  Eagle Pharmaceuticals, Inc. to Present at September Investor Conferences Business Wire
Sep-05-17 10:00AM  Eagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure Business Wire
Aug-22-17 08:01AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Aug-14-17 03:15PM  Eagle Pharmaceuticals, Inc.: Sudden move in price, will it continue? Capital Cube
Aug-11-17 08:05AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit +11.12%
Aug-10-17 08:06AM  See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc. Markit
Aug-09-17 10:25PM  Eagle Pharmaceuticals posts 2Q profit Associated Press +5.09%
06:50AM  Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results Business Wire
Aug-03-17 08:12PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : August 4, 2017 Capital Cube
Jul-31-17 06:50AM  Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2017 Financial Results on August 9, 2017 Business Wire
Jul-26-17 03:11PM  Mizuho Top Analyst Buzzes Mayday as Eagle Pharmaceuticals Inc (EGRX) Valuation Likely to Collapse SmarterAnalyst -23.80%
02:27PM  FDA rejects Eagle Pharmaceuticals' heat stroke treatment Reuters
02:27PM  FDA rejects Eagle Pharmaceuticals' heat stroke treatment Reuters
01:02PM  UPDATE: Eagle Pharma stock plummets 21% on news that heat stroke drug failed to get FDA approval MarketWatch
12:30PM  Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application Business Wire
Jul-25-17 09:19AM  Eagle Pharmaceuticals, Inc. Issues Statement Regarding RYANODEX Application PDUFA Date for Exertional Heat Stroke Business Wire
Jul-24-17 03:38PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 24, 2017 Capital Cube
Jul-20-17 01:30PM  3 Stocks the Smartest Investors Are Buying Right Now Motley Fool
Jul-14-17 02:10PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 14, 2017 Capital Cube
Jul-11-17 09:18AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : July 11, 2017 Capital Cube
Jul-03-17 08:13AM  Key FDA Events to Watch Out for in Jul 2017 Zacks
Jun-26-17 08:39AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : June 26, 2017 Capital Cube
Jun-25-17 09:42AM  These 3 Stocks Are Up Over 500% in the Last 3 Years Motley Fool
Jun-19-17 03:14PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : June 19, 2017 Capital Cube
Jun-16-17 02:34PM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
Jun-08-17 08:56AM  What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX) Zacks
May-31-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June Business Wire
May-25-17 04:10PM  Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts Investor's Business Daily
01:38PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-16-17 08:16AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : May 16, 2017 Capital Cube
May-15-17 06:50AM  Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer Business Wire -13.60%
May-12-17 01:00PM  Edited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
11:56AM  Edited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2017 Health Care Conference Business Wire +8.71%
May-08-17 06:56AM  Eagle Pharmaceuticals posts 1Q profit Associated Press
06:50AM  Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results Business Wire
Apr-25-17 07:00AM  Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017 Business Wire
Apr-24-17 04:30PM  Eagle Pharmaceuticals, Inc. to Present at 42nd Annual Deutsche Bank Health Care Conference Business Wire
02:26PM  ETFs with exposure to Eagle Pharmaceuticals, Inc. : April 24, 2017 Capital Cube
Apr-07-17 08:33AM  15 companies with outsized sales growth and widening profit margins MarketWatch
Apr-05-17 04:43PM  15 companies with outsized sales growth and widening profit margins
Mar-27-17 06:50AM  FDA Grants Priority Review for Eagle Pharmaceuticals Ryanodex NDA for the Treatment of Exertional Heat Stroke Business Wire
Mar-26-17 06:43AM  3 Top Biotech Stocks to Buy in 2017 Motley Fool
Mar-24-17 01:23PM  Director of Eagle Pharmaceuticals Buys Shares
Mar-21-17 01:04PM  EAGLE PHARMACEUTICALS, INC. Financials -7.11%
10:24AM  Eagle Pharma Cancer Drug Secures New Patents Investopedia
08:00AM  Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka Business Wire
Mar-16-17 07:11AM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
07:00AM  Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors Business Wire
Mar-15-17 05:25PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-06-17 10:10AM  New Strong Sell Stocks for March 6th Zacks
Mar-03-17 11:59AM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Capital Cube
Mar-02-17 01:37PM  Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
Mar-01-17 04:36PM  Edited Transcript of EGRX earnings conference call or presentation 1-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
07:07AM  Q4 2016 Eagle Pharmaceuticals Inc Earnings Release - Before Market Open
07:04AM  Eagle Pharmaceuticals posts 4Q profit Associated Press
06:57AM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
06:50AM  Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results Business Wire
Feb-28-17 09:01AM  Eagle Pharmaceuticals Pemetrexed NDA Accepted for Filing by the FDA Business Wire
08:26AM  MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX
07:55AM  Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka Business Wire
Feb-21-17 09:34AM  Eagle Pharmaceuticals Announces New Patents Issued for Bendeka Business Wire
Feb-16-17 07:00AM  Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017 Business Wire
Feb-13-17 04:30PM  Eagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference Business Wire
Feb-01-17 05:30PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
Jan-31-17 04:45PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
Jan-25-17 08:37AM  Falling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX)
Jan-24-17 09:21AM  Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission
Jan-23-17 06:50AM  Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA Business Wire
Jan-16-17 07:44AM  New Strong Sell Stocks for January 16th
Jan-11-17 06:09AM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.31%
Jan-10-17 04:48PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
10:41AM  Eagle Pharmaceuticals, Inc. Value Analysis (NASDAQ:EGRX) : January 10, 2017
Jan-09-17 08:05AM  Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : January 9, 2017 -9.41%
06:12AM  Eagle Pharma downgraded by Mizuho
Jan-06-17 04:39PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -8.55%
Jan-04-17 06:50AM  Eagle Pharmaceuticals to Present at J.P. Morgan 35th Annual Healthcare Conference Business Wire +6.00%
Jan-03-17 06:50AM  Eagle Pharmaceuticals Pemetrexed NDA Submitted for Review Business Wire
Dec-28-16 08:02AM  Myriad Genetics' Unit Releases Favorable Data on Vectra DA
Dec-19-16 05:01PM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
08:00AM  Eagle Pharmaceuticals Announces David Pernock as President and Chief Commercial Officer Business Wire
Dec-14-16 06:03AM  EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-13-16 06:50AM  Eagle Pharmaceuticals Reports Positive Results from Pivotal Animal Study Supporting the Efficacy of RYANODEX for Exertional Heat Stroke Business Wire
Dec-12-16 08:58AM  Why Eagle Pharmaceuticals (EGRX) Could Shock the Market Soon
Dec-05-16 02:04AM  Hedge Funds Arent Crazy About Photronics, Inc. (PLAB) Anymore at Insider Monkey
Nov-28-16 11:28AM  Increased Earnings Estimates Seen for Eagle Pharmaceuticals (EGRX): Can It Move Higher?
Nov-22-16 09:30AM  The Zacks Analyst Blog Highlights: Best Buy, Edgewell Personal Care and Eagle Pharma
Nov-21-16 09:25AM  Black Friday Approaches: Global Week Ahead
07:00AM  Eagle Pharmaceuticals to Present at Piper Jaffray 28th Annual Healthcare Conference Business Wire
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meyers Pete A.Chief Financial OfficerAug 16Buy55.4535019,406700Aug 16 08:30 PM
Braunstein Douglas LDirectorAug 09Buy49.0720,4001,001,087971,000Aug 11 04:34 PM
Meyers Pete A.Chief Financial OfficerJun 12Buy71.4935025,021350Jun 12 04:46 PM
Pernock DavidPres. & Chief Comm. OfficerMay 19Buy79.6925520,321966May 19 04:42 PM
Pernock DavidPres. & Chief Comm. OfficerMay 16Buy82.2420016,448711May 16 05:37 PM
ProQuest Investments IV, L.P.10% OwnerApr 25Option Exercise34.1954,1801,852,67760,957Apr 27 04:19 PM
ProQuest Investments IV, L.P.10% OwnerApr 25Sale88.3854,1804,788,4826,777Apr 27 04:19 PM
ProQuest Investments IV, L.P.10% OwnerApr 03Sale83.1361,4205,105,8453,584,087Apr 03 05:22 PM
ProQuest Investments IV, L.P.10% OwnerMar 31Sale83.0223,6891,966,6613,645,507Apr 03 05:22 PM
ProQuest Investments IV, L.P.10% OwnerMar 30Sale83.006,223516,5093,669,196Apr 03 05:22 PM
ProQuest Investments IV, L.P.10% OwnerMar 29Sale83.0160,8555,051,5746,777Mar 29 05:34 PM
ProQuest Investments IV, L.P.10% OwnerMar 28Sale83.026,182513,2303,734,174Mar 29 05:34 PM
ProQuest Investments IV, L.P.10% OwnerMar 27Sale83.0039,4313,272,7737,277Mar 29 05:34 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 23Option Exercise12.647,02588,8077,025Mar 24 04:41 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 23Sale82.067,025576,4890Mar 24 04:41 PM
ProQuest Investments IV, L.P.10% OwnerMar 23Sale83.0170058,1073,778,087Mar 23 05:02 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 22Option Exercise6.837,10048,5177,100Mar 24 04:41 PM
Edlin Richard A.DirectorMar 22Buy79.446,000476,64029,400Mar 22 04:47 PM
Krill Steven L.EVP & Chief Scientific OfficerMar 22Sale80.097,100568,6410Mar 24 04:41 PM
Pernock DavidPres. & Chief Comm. OfficerMar 21Buy83.98615,123511Mar 21 04:37 PM
ProQuest Investments IV, L.P.10% OwnerMar 21Sale83.1050041,5503,778,787Mar 23 05:02 PM
ProQuest Investments IV, L.P.10% OwnerMar 20Sale82.1051,8834,259,5943,779,287Mar 20 05:40 PM
ProQuest Investments IV, L.P.10% OwnerMar 17Sale82.0138,9973,198,1443,831,170Mar 20 05:40 PM
ProQuest Investments IV, L.P.10% OwnerMar 16Sale82.089,120748,5703,870,167Mar 20 05:40 PM
Pernock DavidPres. & Chief Comm. OfficerMar 09Buy77.8445035,028450Mar 10 07:20 PM
ProQuest Investments IV, L.P.10% OwnerJan 04Sale85.1665,1145,545,1083,879,287Jan 06 04:39 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 23Option Exercise46.095,127236,3035,127Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 23Sale78.615,127403,0180Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 22Option Exercise46.095,126236,2575,126Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 22Sale76.785,126393,5710Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 21Option Exercise37.3310,252382,7427,569Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 21Sale77.1710,252791,1950Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 20Option Exercise12.6310,000126,30010,000Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 20Sale76.6910,000766,8760Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 19Option Exercise12.6410,000126,4077,317Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 19Sale75.6110,000756,0660Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 15Option Exercise9.5910,00095,9286,270Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 15Sale74.7910,000747,8960Jan 04 07:19 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 13Option Exercise4.4210,00044,20010,000Dec 15 04:57 PM
Krill Steven L.EVP & Chief Scientific OfficerDec 13Sale73.6210,000736,1630Dec 15 04:57 PM
RATOFF STEVEN BDirectorDec 13Sale75.008,700652,50013,324Dec 14 04:29 PM
RATOFF STEVEN BDirectorDec 12Sale75.071,30097,59122,024Dec 14 04:29 PM
Krill Steven L.EVP & Chief Scientific OfficerNov 30Option Exercise7.805,78745,1112,530Dec 02 08:56 PM
Krill Steven L.EVP & Chief Scientific OfficerNov 30Sale80.005,787462,9600Dec 02 08:56 PM
FLAUM SANDER ADirectorNov 28Sale78.665,000393,30011,374Nov 30 05:12 PM
Krill Steven L.EVP & Chief Scientific OfficerNov 23Option Exercise8.782001,756200Dec 02 08:56 PM
Krill Steven L.EVP & Chief Scientific OfficerNov 23Sale80.0020016,0000Dec 02 08:56 PM
ProQuest Investments IV, L.P.10% OwnerNov 11Sale85.0015,5511,321,8353,944,401Nov 14 05:40 PM
ProQuest Investments IV, L.P.10% OwnerNov 10Sale85.2818,9351,614,7707,677Nov 14 05:40 PM
ProQuest Investments IV, L.P.10% OwnerNov 09Sale79.42148,80011,818,0653,977,287Nov 09 05:52 PM
ProQuest Investments IV, L.P.10% OwnerNov 07Sale75.395,030379,2124,126,087Nov 09 05:52 PM
ProQuest Investments IV, L.P.10% OwnerNov 04Sale75.0046,1703,462,7504,181,446Nov 04 05:07 PM
ProQuest Investments IV, L.P.10% OwnerNov 02Sale70.10199,60013,992,6357,977Nov 04 05:07 PM